$EVH News

TD Cowen Maintains Buy on Evolent Health, Lowers Price Target to $5

Citigroup Downgrades Evolent Health (EVH)

Citigroup Downgrades Evolent Health to Neutral, Raises Price Target to $6.75

Canaccord Genuity Maintains Buy on Evolent Health, Raises Price Target to $7

Evolent Health: The De-Risking Is Working, But Leverage Keeps Me On Hold

Truist Securities Downgrades Evolent Health (EVH)

Truist Securities Downgrades Evolent Health to Hold, Maintains Price Target to $7

Truist Securities Maintains Buy on Evolent Health, Raises Price Target to $7

Citigroup Maintains Buy on Evolent Health, Raises Price Target to $5.5

Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript

Evolent Health, Inc. 2026 Q1 - Results - Earnings Call Presentation

Needham Maintains Buy on Evolent Health, Raises Price Target to $5

Evolent Health Inc - A (NYSE:EVH) Q1 Revenue Miss Overshadowed by EPS Beat

Evolent Health Affirms FY2026 Sales Guidance of $2.400B-$2.600B vs $2.487B Est.

Evolent Health Q1 Adj. EPS $(0.02) Beats $(0.05) Estimate, Sales $496.246M Miss $534.669M Estimate.

Evolent Health (EVH) Price Target Decreased by 32.38% to 6.01

Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $6

Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $4

UBS Maintains Buy on Evolent Health, Lowers Price Target to $5

Evolent Health: Cheap, Levered, But Ready To Rebound